UNSPSC 51291906: Nitracrine dihydrochloride

This classification denotes an intercalating agent with the molecular formula C18H20N4O2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T450D0Q71D, chemically known as 9-(3-((dimethylamino)propyl)amino)-1-nitroacridine dihydrochloride, but more generally known as nitracrine dihydrochloride, which bears US NIH Compound Identifier 20628. European Medicines Agency schedules nitracrine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09314MIG.

Most nations, for tariff purposes, schedule nitracrine dihydrochloride under HS 29339990. SMILES: CN(C)CCCNC1C2CCCCC2NC3C1C(CCC3)[N+](=O)[O-].CL.CL.

UNSPSC 51291906 Nitracrine dihydrochloride is a Commodity code, but recent state and local procurement activity under this code shows minimal relevance to the pharmaceutical ingredient specified in its name. The source records three recent opportunities tagged to this code, yet only one directly involves pharmaceutical procurement; the other two address naloxone distribution systems and a pharmacy benefit program structure—neither of which are nitracrine-related. State and local governments do solicit pharmaceutical products through cooperative purchasing vehicles and direct procurement, but the available record does not show active demand specifically for nitracrine dihydrochloride. The issuing bodies in the recent record include a Florida county health department, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), representing the mix of county health authorities, state health agencies, and multi-state cooperative frameworks that typically drive pharmaceutical procurement.

The geographic spread evident in the recent opportunities spans Florida, Texas, and Minnesota, with MMCAP's cooperative framework also extending to Oregon. The most concrete pharmaceutical procurement example is MMCAP's January 2026 RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) with contract effectiveness July 1, 2026; evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and the remainder on administrative compliance and EDI capability. Seminole County, Florida issued an IFB (IFB60459723LAS) in June 2026 for naloxone and drug deactivation systems with a response deadline of July 26, 2023—a date that is now in the past, rendering this opportunity closed. Texas HHS issued an RFI in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program, signaling exploratory procurement activity rather than immediate contract awards. The code's current signal is weak for nitracrine specifically; firms should verify whether the code mismatch reflects a labeling error or whether their nitracrine product qualifies under broader pharmaceutical commodity codes.